Evidence map›Paper›PMID 24604720›Full record

ArticleJournal of cellular biochemistry2014

Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.

Naoki Terada, Takumi Shiraishi, Yu Zeng, Koh-Meng Aw-Yong, Steven M Mooney, Zhi Liu, Sayuri Takahashi, Jun Luo, Shawn E Lupold, Prakash Kulkarni and 1 more

Abstract read
In one paragraph

Article in Journal of cellular biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Naoki TeradaDepartments of Urology, Oncology, Pharmacology and Molecular Sciences, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Takumi Shiraishi
Yu Zeng
Koh-Meng Aw-Yong
Steven M Mooney
Zhi Liu
Sayuri Takahashi
Jun Luo
Shawn E Lupold
Prakash Kulkarni
Robert H Getzenberg
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
TRANS_NETWORK PROJECTSU54CA143803 · NCI · PRINCETON UNIVERSITY · PI STURM, JAMES C · 2009 to 2013
$14.2M
MicroRNAs in Advanced Prostate Cancer: A miR-21 modelR01CA143299 · NCI · JOHNS HOPKINS UNIVERSITY · PI LUPOLD, SHAWN · 2010 to 2014
$1.6M
NCI NIH HHS 1R01CA143299NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA143299NCI NIH HHS U54 CA143803NCI NIH HHS U54CA143803
6 · The paper itself

Abstract

Prostate cancer is a heterogeneous disease and thus, it is important to understand whether among the heterogeneous collection of cell types, androgen-deprivation insensitive cells exist prior to hormonal manipulation. We established several LNCaP subclones with distinct insensitivities to androgen deprivation from a parental LNCaP cell line. In the resulting clones, the sensitivity to androgen-deprivation negatively correlated with their PSA expression levels. In two of these clones, an androgen insensitive clone, LNCaP-cl1, and an androgen sensitive clone, LNCaP-cl5, the DNA copy number differed significantly, indicating that these clones contain genetically distinct cells. LNCaP-cl1 had higher PSA expression but lower invasiveness and tumor growth potential than LNCaP-cl5. The expression levels of two genes that are known to be regulated by miR-21, an androgen-regulated microRNA, Sprouty1 (SPRY1) and Jagged1 (JAG1) were significantly lower in LNCaP-cl1 than in LNCaP-cl5. Knocking down SPRY1 in LNCaP cells enhanced PSA expression and cell proliferation. JAG1 administration in LNCaP cells enhanced cell invasion and JAG1 knockdown in PC3 cells suppressed cell invasion and tumor formation. These results indicated that the expression differences in SPRY1 and JAG1 may contribute to the phenotypic differences between the LNCaP-cl1 and LNCaP-cl5 clones. In tissue samples, SPRY1 expression levels were significantly lower in prostate cancer patients with PSA recurrence after surgical treatment (P = 0.0076) and JAG1 expression levels were significantly higher in Gleason sum (GS) 8-9 disease than in GS 5-6 (P = 0.0121). In summary a random population of LNCaP cells comprises a heterogeneous group of cells with different androgen-deprivation sensitivities and potential for invasiveness.

Indexed as

AndrogensAnimalsCalcium-Binding ProteinsCell Line, TumorCell ProliferationDNA Copy Number VariationsGene Knockdown TechniquesHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinMaleMembrane ProteinsMice, SCIDMicroRNAsNeoplasm InvasivenessNeoplasm TransplantationAndrogensCalcium-Binding ProteinsIntercellular Signaling Peptides and ProteinsJAG1 protein, humanJag1 protein, mouseJagged-1 ProteinMembrane ProteinsMicroRNAsMIRN21 microRNA, humanPhosphoproteinsProstate-Specific AntigenSerrate-Jagged ProteinsSPRY1 protein, humanANDROGEN SENSITIVEMARKERPROSTATE CANCER

Identifiers

PMID24604720
PMCPMC4337863
OpenAlexW1586722981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.